Table 2.
Clinical, biochemical, and hematological parameters of all the nine patients before, one-month follow-up and after treatment
| Mean (SD) value |
|||
|---|---|---|---|
| Parameter | Baseline value | One-month follow-up (Post-VL treatment with SDA) | End of treatment |
| Body Temperature (oF) | 100.3(1.79) | 97.65(0.44) | 97.66(0.49) |
| Weight (kg) | 41(1.17) | 43.11(1.14) | 44.55(1.04) |
| Spleen (cm below left costal margin) | 6(4.2) | 2.1(3.14) | 1(0.86) |
| Liver (cm below right costal margin) | 1.6(1) | 0.33(0.50) | 0.33(0.55) |
| Hemoglobin (g/dl) | 8.35(2.43) | 9.4(1.89) | 10.2(1.17) |
| WBC (Per micro-liter) | 2811(1.49) | 5831(9.15) | 5170(1.07) |
| Neutrophil (% of leucocytes) | 32.11(9.18) | 40.78(6.32) | 61.66(8.30) |
| Lymphocyte (% of leucocytes) | 60.22(9.39) | 53(4.840) | 37(7.35) |
| Eosinophil (% of leucocytes) | 3.22(3.56) | 2.66(2.18) | 1.33(1.22) |
| Platelet (per micro-liter) | 1.24(3.46) | 1.81(4.40) | 2.20(6.85) |
| Albumin (g/dl) | 3.72(0.17) | 3.84(0.19) | 3.91(0.105) |
| Globulin (g/dl) | 3.63(0.20) | 3.38(0.21) | 3.13(0.17) |
| Serum Creatinine (mg/dl) | 1.05(0.30) | 0.94(0.21) | 0.88(0.08) |
| Serum Urea (mg/dl) | 26(3.74) | 24(3.31) | 25.33(3.53) |
| Serum total bilirubin (mg/dl) | 0.96(0.17) | 0.85(0.07) | 0.78(0.10) |
| Aspartate amino transferase (U/liter) | 1.16(1.32) | 39.5(1.27) | 34.55(4.24) |
| Alanine amino transferase (U/liter) | 85.66(7.95) | 40.11(1.21) | 36.55(1.04) |
| Serum NA+ (mmol/liter) | 138(3.85) | 139(2) | 139(1.09) |
| Serum K+ (mmol/liter) | 3.95(0.23) | 3.63(0.22) | 3.67(0.14) |
| Parasitic score(skin smear) | 2.2(1.2) | 1.2(0.44) | 0 |
| Parasitic score(SA/BMA) | 3.1(1.05) | 0 | 0 |
| Prothrombin time (patient value) | 14.4(1.7) | 13 (1.1) | 12.5 (1.1) |
| Result of HIV | Negative | Negative | Negative |
| HBsAg | Negative | Negative | Negative |
| HCV | Negative | Negative | Negative |
Notes: SA: Splenic aspiration, BMA: Bone marrow aspiration
SDA: Single-dose AmBisome(10 mg/kg)
End of treatment was the completion of 12 weeks courses of Miltefosine for PKDL.